Investigation Uncovers Troubling Safety Data Regarding Diabetes Drugs.

Evidence of potential harms from new GLP-1 diabetes drugs has not been published, and independent studies challenge the conclusions of the drugs manufacturers' research, according to a BMJ investigation. Researchers who reviewed regulatory documents found unpublished data pointing to "unwanted proliferative or inflammatory pancreatic effects." The investigation also revealed that companies have not done certain critical safety studies; nor have regulators requested them yet. Also, access to some of the raw data regarding the safety of these drugs has been denied. Later this month, the NIH will hold a meeting on possible links between diabetes drugs and pancreatic cancer.